SP51

SP51 is a serpin-derived peptide therapeutic candidate developed by Serpin Pharma for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). It is part of a proprietary family of peptides designed to mimic the anti-inflammatory and pro-resolving properties of Alpha-1 Antitrypsin (AAT). The drug's mechanism of action involves the activation of the Low-density lipoprotein receptor-related protein 1 (LRP1), a receptor that modulates inflammatory responses and promotes tissue repair and resolution. By targeting LRP1, SP51 aims to mitigate the nerve damage and associated pain caused by neurotoxic chemotherapy agents. According to Serpin Pharma's pipeline, SP51 is currently listed as 'Licensed,' indicating that development or commercialization rights have been out-licensed to a partner for further advancement.